32 results about "Melanopsin" patented technology

ABSTRACT OF THE DISCLOSURE The newly discovered retinal ganglion cell photoreceptor melanopsin absent in the central fovea of the eye but distributed throughout the remaining human retinal body provides both non-visual biological / physiological input inducing circadian entrainment, and visual input affecting perceived brightness; this perceived brightness is not the object brightness commonly associated with luminance and perceived color of an object in central view, but the perception of brightness of a whole space or task background. Discussed are improvements to circadian lighting systems based on melanopsin stimulation whereby ambient and / or device background lighting may be temporally tuned over a range of prescribed color temperatures from a first subset of lighting having a higher melanopic content to a second subset of lighting having a lower melanopic content or vice versa in accordance with a desired circadian cycle, and in a manner where net light output is of a constant perceived brightness and color throughout temporal tuning.

The present invention relates to a GFP-CAP peptide having an amino acid sequence derived from TGF-β1 (transforming growth factor-β1) and a cell adhesion sequence, wherein the amino acid sequence derived from TGF-β1 consists of the amino acid sequence of SEQ ID NO:1 and the TGFP-CAP peptide is represented by the following formula I: Ile-Trp-Ser-Leu-Asp-Thr-Gln-Tyr-Cell adhesion sequence (I). The TGFP-CAP peptide of the present invention exhibits excellent anti-angiogenic activity. In addition, the TGFP-CAP peptide of the present invention prevents effectively melanin generation in skin to have skin whitening effects. The present peptide shows much higher stability and permeability to skin than natural-occurring TGF-β1. Such plausible activities and safety of the present peptide enable advantageously to application to drugs, quasi-drugs and cosmetics.

Methods of weight treatment in animals are presented including: stimulating a retinal ganglia of the animal by an exposure to a narrow spectrum light. In some embodiments, the stimulating the retinal ganglia of the animal is associated with a stimulation of melanopsin. In some embodiments, the stimulation of melanopsin is associated with a inhibition of melatonin secretion. In some embodiments, inhibition of melatonin secretion is associated with a stimulation of leptin secretion. In some embodiments, the stimulation of leptin secretion is associated with a decrease in appetite in the animal. In some embodiments, the exposure to the narrow spectrum light is associated with a weight loss in the animal. In some embodiments, the narrow spectrum light is in a spectrum range of approximately 435 to 520 nanometers.